非筋肉浸潤性膀胱がんの世界市場

非筋肉浸潤性膀胱がんの世界市場は2030年までに89億米ドルに達する見込み

2024年に31億米ドルと推定される非筋肉浸潤性膀胱がんの世界市場は、2024～2030年の分析期間においてCAGR 19.5%で成長し、2030年には89億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである免疫療法治療は、CAGR18.9%を記録し、分析期間終了時には45億米ドルに達すると予測されます。化学療法治療セグメントの成長率は、分析期間中CAGR 21.0％と推定されます。

米国市場は8億3,420万米ドルと推定、中国はCAGR26.2％で成長予測

米国の非筋肉浸潤性膀胱がん市場は、2024年に8億3,420万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは26.2%です。その他の注目すべき地域別市場としては日本とカナダがあり、分析期間中のCAGRはそれぞれ15.7%と17.3%と予測されています。欧州では、ドイツがCAGR約16.3%で成長すると予測されています。

世界の非筋肉浸潤性膀胱がん市場- 主要動向と促進要因のまとめ

非筋肉浸潤性膀胱がんが泌尿器腫瘍学および個別化がん治療で注目される理由とは？

非筋肉浸潤性膀胱がん（NMIBC）にはTa期、T1期、非浸潤がん（CIS）が含まれ、世界中で新たに診断された膀胱がん症例の70～75％近くを占めています。これらの腫瘍は膀胱壁の粘膜または粘膜下層に限局しているが、再発率が高く、進行する可能性があるため、NMIBCは複雑な臨床的課題となっています。NMIBCの治療には、的確なサーベイランス、繰り返しの介入、治療効果とQOLおよび費用負担のバランスをとるための患者に合わせた治療が必要です。

特に高齢者、喫煙者、発がん物質への職業的曝露を有する集団における膀胱がんの罹患率の上昇は、NMIBCの臨床的および経済的意義を高めています。泌尿器科医、腫瘍医、医療システムは、早期発見、リスク層別化、筋層浸潤性疾患への進行を遅延または予防するための維持療法を重視しています。分子診断学、高度画像診断、非侵襲的尿バイオマーカーの統合により、診断精度とサーベイランスの効率はさらに向上しています。治療パラダイムが、侵襲的で一般的なアプローチから、個別化された膀胱内免疫療法や分子標的薬へと移行するにつれて、NMIBCは世界のがん治療において優先順位の高い分野と見なされるようになってきています。

免疫療法、膀胱内ドラッグデリバリー、バイオマーカーは、NMIBC治療をどのように変えていくのか？

カルメット菌（BCG）療法は、依然として高リスクのNMIBCに対するゴールドスタンダードであるが、世界の不足、不耐性、治療の失敗により、代替の膀胱内薬剤の技術革新が促されています。N-803（IL-15アゴニスト）、チェックポイント阻害剤（アテゾリズマブ、ペムブロリズマブなど）、遺伝子組換えBCG株などの新規免疫治療薬が、BCGに反応しない患者や難治性患者を対象に臨床開発が進められています。これらの治療法は、全身毒性を最小限に抑えながら、膀胱粘膜内での抗腫瘍免疫活性化を高めることを目的としています。

温熱化学療法、徐放性ゲル、EMDA（Electromotive Drug Administration）などのドラッグデリバリーの革新は、膀胱内の薬物滞留性と粘膜浸透性を向上させています。遺伝子治療ベクター（ナドファラゲンフィラデノベックなど）、エピジェネティックモジュレーター、FGFR阻害剤などの標的薬剤は、臨床試験で有望視されています。分子リスクプロファイリングと尿ベースのアッセイ（UroVysion、Cxbladderなど）は、再発の早期発見と治療強度の指針となっています。これらの進歩により、NMIBC治療は、治療上のブレークスルーをもたらす可能性の高い、免疫学的知見に基づく局所がん管理のモデルとして位置づけられています。

NMIBC治療薬とモニタリングの需要を形成している患者層とヘルスケアシステムは？

主な患者層は60歳以上の男性で、タバコの使用歴や工業化学物質への曝露歴があることが多いです。NMIBC患者の多くは、再発リスクが高いため生涯にわたる監視が必要であり、膀胱鏡による経過観察、画像診断、膀胱内治療に対する継続的な需要が生じています。腫瘍の大きさ、多発性、悪性度によって分類される中・高リスク患者は、より積極的な免疫療法や化学切除レジメンの需要を牽引しています。

地域情勢別では、北米と西欧が、先進的な泌尿器科インフラ、BCGと膀胱鏡検査に対する償還、活発な臨床試験活動により、NMIBC治療において優位を占めています。アジア太平洋は、膀胱がんの有病率が増加し、先進的な診断法や治療法へのアクセスが進化していることから、急成長地域として浮上しています。日本、韓国、中国のような国々では、規制当局の承認が拡大し、腫瘍学の革新への投資が行われています。一方、中低所得国は、BCGへのアクセスや診断の遅れが課題であるが、モバイル診断や膀胱がん啓発プログラムを通じて将来の成長機会をもたらしています。

NMIBC治療薬市場の長期的成長とイノベーションの原動力は？

アンメットBC治療薬市場の成長は、満たされていない臨床ニーズ、高い再発負担、免疫腫瘍学および局所ドラッグデリバリープラットフォームのパイプラインの拡大によってもたらされます。BCGの不足と治療抵抗性が蔓延する中、再発と進行のリスクを低減する新規の膀胱温存療法の機会が拡大しています。BCGに反応しないNMIBCに対するFDAの早期承認のような規制上の道筋は、この分野におけるバイオ医薬品の技術革新を促しています。

製薬企業は泌尿器科学会、CRO、病院ネットワークとパートナーシップを結び、膀胱内薬剤の開発を加速させ、臨床試験へのアクセスを拡大しています。市場の成長は、デジタル監視プラットフォーム、AIベースの画像解析、再発検出を改善し治療を個別化する予測バイオマーカーによっても支えられています。膀胱温存が中心的な治療目標になりつつあり、効果的でありながら低侵襲な選択肢を患者が求めていることから、NMIBCは将来のがん治療においてダイナミックで可能性の高いセグメントであり続けると思われます。

セグメント

治療タイプ（免疫療法、化学療法、標的療法）、がんタイプ（低悪性度膀胱がん、高悪性度膀胱がん）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例（注目の43社）

• AstraZeneca plc
• Bristol Myers Squibb Company
• CG Oncology
• Eli Lilly and Company
• Ferring Pharmaceuticals
• GlaxoSmithKline plc（GSK）
• Herantis Pharma Oyj
• ImmunityBio, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Protara Therapeutics, Inc.
• Roche Holding AG
• Sanofi S.A.
• Sesen Bio, Inc.
• TARIS Biomedical LLC
• Theralase Technologies Inc.
• UroGen Pharma Ltd.
• Viventia Bio Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Non-Muscle Invasive Bladder Cancer Market to Reach US$8.9 Billion by 2030

The global market for Non-Muscle Invasive Bladder Cancer estimated at US$3.1 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 19.5% over the analysis period 2024-2030. Immunotherapy Treatment, one of the segments analyzed in the report, is expected to record a 18.9% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Chemotherapy Treatment segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$834.2 Million While China is Forecast to Grow at 26.2% CAGR

The Non-Muscle Invasive Bladder Cancer market in the U.S. is estimated at US$834.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 26.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.7% and 17.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.3% CAGR.

Global Non-Muscle Invasive Bladder Cancer Market - Key Trends & Drivers Summarized

Why Is Non-Muscle Invasive Bladder Cancer Drawing Focus in Urologic Oncology and Personalized Cancer Therapies?

Non-muscle invasive bladder cancer (NMIBC), which includes stages Ta, T1, and carcinoma in situ (CIS), represents nearly 70-75% of all newly diagnosed bladder cancer cases worldwide. Although these tumors are confined to the mucosa or submucosa of the bladder wall, their high recurrence rate and potential for progression make NMIBC a complex clinical challenge. The management of NMIBC requires precise surveillance, repeated interventions, and patient-tailored therapies to balance treatment efficacy with quality of life and cost burden.

The rising incidence of bladder cancer-particularly among older adults, smokers, and populations with occupational exposure to carcinogens-is elevating the clinical and economic significance of NMIBC. Urologists, oncologists, and health systems are emphasizing early detection, risk stratification, and maintenance therapies to delay or prevent progression to muscle-invasive disease. The integration of molecular diagnostics, advanced imaging, and non-invasive urine-based biomarkers is further improving diagnostic accuracy and surveillance efficiency. As treatment paradigms shift from invasive, generalized approaches to personalized intravesical immunotherapies and targeted agents, NMIBC is increasingly viewed as a high-priority segment within global oncology care.

How Are Immunotherapies, Intravesical Drug Delivery, and Biomarkers Transforming NMIBC Treatment?

Bacillus Calmette-Guerin (BCG) therapy remains the gold standard for high-risk NMIBC, but global shortages, intolerance, and treatment failures are prompting innovation in alternative intravesical agents. Novel immunotherapeutics such as N-803 (IL-15 agonist), checkpoint inhibitors (e.g., atezolizumab, pembrolizumab), and recombinant BCG strains are under advanced clinical development for BCG-unresponsive or refractory patients. These therapies aim to enhance anti-tumor immune activation within the bladder mucosa while minimizing systemic toxicity.

Drug delivery innovations-such as thermochemotherapy, sustained-release gels, and electromotive drug administration (EMDA)-are improving intravesical drug retention and mucosal penetration. Targeted agents like gene therapy vectors (e.g., nadofaragene firadenovec), epigenetic modulators, and FGFR inhibitors are showing promise in clinical trials. Molecular risk profiling and urine-based assays (e.g., UroVysion, Cxbladder) are supporting earlier detection of recurrence and guiding treatment intensity. These advances are positioning NMIBC therapy as a model of localized, immunologically-informed cancer management with high potential for therapeutic breakthroughs.

Which Patient Segments and Healthcare Systems Are Shaping Demand for NMIBC Therapeutics and Monitoring?

The primary patient population comprises individuals aged 60 and older, predominantly male, often with a history of tobacco use or exposure to industrial chemicals. Many NMIBC patients require lifelong surveillance due to the high recurrence risk, creating ongoing demand for cystoscopic follow-ups, imaging, and intravesical treatments. Intermediate- and high-risk patients-classified based on tumor size, multiplicity, and grade-drive demand for more aggressive immunotherapeutic and chemoablative regimens.

Geographically, North America and Western Europe dominate the NMIBC treatment landscape due to advanced urology infrastructure, reimbursement for BCG and cystoscopy, and robust clinical trial activity. Asia-Pacific is emerging as a fast-growing region with increasing bladder cancer prevalence and evolving access to advanced diagnostics and therapies. Countries like Japan, South Korea, and China are seeing expanded regulatory approvals and investments in oncology innovation. Low- and middle-income nations, meanwhile, are challenged by BCG access and delayed diagnosis but represent future growth opportunities through mobile diagnostics and bladder cancer awareness programs.

What Is Fueling Long-Term Growth and Innovation in the NMIBC Therapeutics Market?

The growth in the NMIBC therapeutics market is driven by unmet clinical needs, high recurrence burden, and the expanding pipeline of immuno-oncology and localized drug delivery platforms. As BCG shortages and treatment resistance become more prevalent, the opportunity for novel bladder-preserving therapies that reduce recurrence and progression risk is expanding. Regulatory pathways such as FDA’s accelerated approval for BCG-unresponsive NMIBC are encouraging biopharmaceutical innovation in this space.

Pharmaceutical firms are forming partnerships with urology societies, CROs, and hospital networks to accelerate intravesical drug development and expand access to clinical trials. Market growth is also supported by digital surveillance platforms, AI-based imaging analysis, and predictive biomarkers that improve recurrence detection and personalize treatment. With bladder preservation becoming a core therapeutic goal and patients demanding effective yet minimally invasive options, NMIBC will remain a dynamic, high-potential segment in the future of oncology therapeutics.

SCOPE OF STUDY:

The report analyzes the Non-Muscle Invasive Bladder Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Immunotherapy, Chemotherapy, Targeted Therapy); Cancer Type (Low Grade Bladder Cancer, High Grade Bladder Cancer); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AstraZeneca plc
• Bristol Myers Squibb Company
• CG Oncology
• Eli Lilly and Company
• Ferring Pharmaceuticals
• GlaxoSmithKline plc (GSK)
• Herantis Pharma Oyj
• ImmunityBio, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Protara Therapeutics, Inc.
• Roche Holding AG
• Sanofi S.A.
• Sesen Bio, Inc.
• TARIS Biomedical LLC
• Theralase Technologies Inc.
• UroGen Pharma Ltd.
• Viventia Bio Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Non-Muscle Invasive Bladder Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Early-Stage Cancer Detection Rates Propel Growth in Non-Muscle Invasive Bladder Cancer Therapies
  • Increased Availability of Cystoscopic Screening Throws the Spotlight on Early Diagnosis Strategies
  • Regulatory Approvals of Novel Intravesical Therapies Strengthen Business Case for Targeted Treatments
  • Growing Adoption of Blue Light Cystoscopy Enhances Accuracy and Drives Demand for Diagnostic Devices
  • Emergence of Immune Checkpoint Inhibitors Expands Addressable Market in High-Risk NMIBC
  • Expansion of Bladder-Sparing Treatment Protocols Sustains Demand for Intravesical Drug Delivery
  • Innovation in Mitomycin and BCG Formulations Drives Product Differentiation
  • Integration of Liquid Biopsy and Urinary Biomarkers Supports Personalized Therapy Approaches
  • Rising Incidence of Bladder Cancer in Aging Populations Spurs Market Expansion
  • Reimbursement Coverage for Outpatient Intravesical Therapies Enhances Treatment Accessibility
  • Development of Drug-Eluting Implants and Devices Accelerates Shift Toward Sustained Drug Release
  • Increased Focus on BCG Shortage Management Spurs Innovation in Alternative Immunotherapies
  • Clinical Guidelines Supporting Risk-Stratified Treatment Pathways Drive Tailored Therapeutic Adoption
  • Availability of Real-World Evidence Enhances Clinical Confidence in Emerging Therapies
  • Surge in Cancer Recurrence Awareness Propels Need for Long-Term Surveillance Solutions
  • Collaborations Between Pharma Companies and Urology Clinics Strengthen Pipeline Validation
  • Challenges in Adherence to Multi-Cycle Intravesical Regimens Create Need for Patient-Centric Innovations
  • Rise in Tele-Urology Consultations Facilitates Remote Monitoring and Follow-Up
  • Expansion of Clinical Trials in NMIBC Supports Innovation in Drug Combinations and Sequencing
  • Variability in Global Treatment Protocols Creates Market Fragmentation Across Regions
  • Emphasis on Quality-of-Life Outcomes Strengthens Interest in Non-Surgical Treatment Options
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Non-Muscle Invasive Bladder Cancer Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Non-Muscle Invasive Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Low Grade Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Low Grade Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Low Grade Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for High Grade Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for High Grade Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for High Grade Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• JAPAN
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• CHINA
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• EUROPE
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Non-Muscle Invasive Bladder Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• FRANCE
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• GERMANY
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Non-Muscle Invasive Bladder Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• INDIA
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Non-Muscle Invasive Bladder Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Non-Muscle Invasive Bladder Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• AFRICA
  • Non-Muscle Invasive Bladder Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Non-Muscle Invasive Bladder Cancer by Treatment Type - Immunotherapy, Chemotherapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Non-Muscle Invasive Bladder Cancer by Cancer Type - Low Grade Bladder Cancer and High Grade Bladder Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Cancer Type - Percentage Breakdown of Value Sales for Low Grade Bladder Cancer and High Grade Bladder Cancer for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Non-Muscle Invasive Bladder Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION